SecBot SecBot
Insider Buy ·Filed Jun 29, 2026

ARTV

Artiva Biotherapeutics, Inc.
BULLISH
Impact 4/10
Horizonweeks Processed4mo ago SEC0001231919-26-000711
Insider cluster: 1 insiders, $292K total
Actionable Insight ▲ Bullish

The single-insider purchase by RA Capital (a 10% owner/Director) is a standalone bullish signal per insider-trading literature, though at 0.12% of market cap it is not large enough to force immediate re-rating. Monitor for additional insider buying or a material event filing (pipeline catalyst, partnership, financing) that could explain the concentrated buying.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.70
T+0 close · Jun 29, 2026 · via day close
Latest settled
−22.78%
T+60 · $7.49
Vs SPY
−25.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $9.70entry
  2. T+1 · 5mo ago +1.03%α +1.17% · $9.80
  3. T+5 · 4mo ago −2.68%α −3.28% · $9.44
  4. T+20 · 4mo ago +6.39%α +7.42% · $10.32
  5. T+60 · 8w ago −22.78%α −25.52% · $7.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

RA Capital Management, a 10% owner and director at Artiva Biotherapeutics, purchased ~32.9K shares for $292K over two days.

Key Financial Metrics

Direction
buying
Total Value
$292.0K
Insiders
1

Key Facts

  • RA Capital Management, a 10% owner/Director, bought 31K shares at $8.88 ($275K) on 6/25 and 1.9K shares at $8.98 ($17K) on 6/26
  • Total insider purchase value: $292K
  • Purchase represents ~0.12% of $242M market cap
  • ARTV has 92% analyst bullish rating (4 Strong Buy, 7 Buy, 1 Hold)

Financial Impact

$292K insider purchase, ~0.12% of market cap

insider_ownershipdilution

Risk Factors

  • Purchase value is small relative to market cap (0.12%), limiting signal strength
  • Insider buying preceded by strong recent price performance (+35% on prior report) creates potential mean-reversion risk
  • Biotech sector binary risk (pipeline failure, financing overhang) independent of insider activity

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001231919-26-000711

Track record

33 reports on ARTV

Performance horizon

10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 5h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026